These results suggest that while cardiotoxic cancer therapies may unmask the harmful cardiac effects of rare PAVs in TTN and other DCM genes, leading to early-onset CCM, these variants may not significantly increase the risk of late-onset CCM, which typically develops years to decades after a childhood cancer diagnosis. This evidence concerns the gene TTN and cancer.